Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27101009 | 0.84 | PDE10A (0.36) | ALDH1A1POLBHTT | |
| SCHEMBL23520672 | 0.84 | PARP1 (0.44) | PARP1KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29343954 | 0.82 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL30634862 | 0.81 | PRNP (0.38) | KDM4EALDH1A1SMN1; SMN2KMT2AHTT | |
| SCHEMBL17884005 | 0.81 | PRNP (0.38) | KDM4EALDH1A1SMN1; SMN2KMT2AHTT | |
| SCHEMBL26671293 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL11608932 | 0.81 | KDM4E (0.46) | PARP1KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4184952 | 0.81 | DHODH (0.41) | PARP1ALDH1A1HTTDHODH | |
| SCHEMBL20660532 | 0.78 | APP (0.37) | ALDH1A1SMN1; SMN2HTTMAPTXBP1 | |
| SCHEMBL12134833 | 0.78 | ACHE (0.39) | KDM4EALDH1A1SMN1; SMN2KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230262-A1 | TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| US-4102885-A | Process for preparing 2,4-dihaloquinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | PARP1 1853/4885KDM4E 812/4885ALDH1A1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.